SurgiLight
This article was originally published in The Gray Sheet
Executive Summary
Two-for-one stock split for shareholders of record Jan. 25 is effective Jan. 27. The Orlando, Florida company is preparing an FDA investigational device exemption submission for use of its IR-3000 infrared laser system for presbyopia reversal. Trials are slated to start by mid-2000 (1"The Gray Sheet" Nov. 8, p. 19)